pmc logo imageJournal ListSearchpmc logo image
Logo of brheartjJournal URL: redirect3.cgi?&&auth=0DQzuwRKIJNx8JS2FGF-3EVVRENmESRPmNtxC1QCE&reftype=publisher&artid=484125&article-id=484125&iid=15433&issue-id=15433&jid=160&journal-id=160&FROM=Article|Banner&TO=Publisher|Other|N%2FA&rendering-type=normal&&http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=159&action=archive
Br Heart J. 1995 December; 74(6): 660–663.
PMCID: PMC484125
Appetite suppressants and primary pulmonary hypertension in the United Kingdom.
S. H. Thomas, A. Y. Butt, P. A. Corris, J. J. Egan, T. W. Higenbottam, B. P. Madden, and P. C. Waller
Wolfson Unit of Clinical Pharmacology, University of Newcastle upon Tyne, Newcastle.
Abstract
OBJECTIVE--Amphetamine-like appetite suppressants, particularly fenfluramines, have been implicated in the aetiology of primary pulmonary hypertension. At one specialist centre in France 20% of patients with primary pulmonary hypertension had been exposed to fenfluramine. The prevalence of primary pulmonary hypertension associated with fenfluramines and other appetite suppressants in the United Kingdom is unknown. This study was performed to measure prior exposure to appetite suppressants in patients with primary pulmonary hypertension. SETTING--Heart lung transplantation centres in England. PATIENTS--United Kingdom residents with proven primary pulmonary hypertension referred for consideration of heart lung transplantation. METHODS--Case surveillance study, obtaining data from the hospital and general practitioner's notes and directly from the patients or their relatives. RESULTS--55 patients were identified. Drug histories were available from hospital records in all patients, from the general practitioner's notes in 51, and from the patients or relatives in 44. Of these, 3 female patients had been exposed to appetite suppressants (2 fenfluramine, 1 diethylpropion): 2 have since died. In each case exposure was brief and apparently predated the development of symptoms by several years. CONCLUSIONS--Exposure of patients with severe primary pulmonary hypertension to fenfluramine and other appetite suppressants is uncommon in the United Kingdom unlike in France, where most of the cases associating primary pulmonary hypertension with fenfluramine use have originated. This may reflect more conservative prescribing of these agents in the United Kingdom.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (964K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Butt, AY; Higenbottam, T. New therapies for primary pulmonary hypertension. Chest. 1994 Feb;105(2 Suppl):21S–25S. [PubMed]
  • Follath, F; Burkart, F; Schweizer, W. Drug-induced pulmonary hypertension? Br Med J. 1971 Jan 30;1(5743):265–266. [PubMed]
  • Kay, JM; Smith, P; Heath, D. Aminorex and the pulmonary circulation. Thorax. 1971 May;26(3):262–270. [PubMed]
  • Loogen, F; Worth, H; Schwan, G; Goeckenjan, G; Lösse, B; Horstkotte, D. Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa. 1985;27(2-3):111–124. [PubMed]
  • Cameron, J; Waugh, L; Loadsman, T; White, P; Radford, DJ. Possible association of pulmonary hypertension with an anorectic drug. Med J Aust. 1984 May 12;140(10):595–597. [PubMed]
  • Nall, KC; Rubin, LJ; Lipskind, S; Sennesh, JD. Reversible pulmonary hypertension associated with anorexigen use. Am J Med. 1991 Jul;91(1):97–99. [PubMed]
  • Malmquist, J; Trell, E; Torp, A; Lindström, C. A case of drug-induced (?) pulmonary hypertension. Acta Med Scand. 1970 Oct;188(4):265–272. [PubMed]
  • Douglas, JG; Munro, JF; Kitchin, AH; Muir, AL; Proudfoot, AT. Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed). 1981 Oct 3;283(6296):881–883. [PubMed]
  • Gaul, G; Blazek, G; Deutsch, E; Heeger, H. Ein Fall von chronischer pulmonaler Hypertonie nach Fenfluramineinnahme. Wien Klin Wochenschr. 1982 Nov 26;94(22):618–622. [PubMed]
  • McMurray, J; Bloomfield, P; Miller, HC. Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J (Clin Res Ed). 1986 Jan 25;292(6515):239–240. [PubMed]
  • Pouwels, HM; Smeets, JL; Cheriex, EC; Wouters, EF. Pulmonary hypertension and fenfluramine. Eur Respir J. 1990 May;3(5):606–607. [PubMed]
  • Atanassoff, PG; Weiss, BM; Schmid, ER; Tornic, M. Pulmonary hypertension and dexfenfluramine. Lancet. 1992 Feb 15;339(8790):436. [PubMed]
  • Roche, N; Labrune, S; Braun, JM; Huchon, GJ. Pulmonary hypertension and dexfenfluramine. Lancet. 1992 Feb 15;339(8790):436–437. [PubMed]
  • Brenot, F; Herve, P; Petitpretz, P; Parent, F; Duroux, P; Simonneau, G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 1993 Dec;70(6):537–541. [PubMed]
  • Kleiger, RE; Boxer, M; Ingham, RE; Harrison, DC. Pulmonary hypertension in patients using oral contraceptives. A report of six cases. Chest. 1976 Feb;69(2):143–147. [PubMed]
  • Fahlén, M; Bergman, H; Helder, G; Rydén, L; Wallentin, I; Zettergren, L. Phenformin and pulmonary hypertension. Br Heart J. 1973 Aug;35(8):824–828. [PubMed]
  • Neely, CF; Haile, D; Matot, I. Tone-dependent responses of 5-hydroxytryptamine in the feline pulmonary vascular bed are mediated by two different 5-hydroxytryptamine receptors. J Pharmacol Exp Ther. 1993 Mar;264(3):1315–1326. [PubMed]
  • Bradley, JD; Zanaboni, PB; Dahms, TE. Species differences in pulmonary vasoactive responses to histamine, 5-hydroxytryptamine, and KCl. J Appl Physiol. 1993 Jan;74(1):139–146. [PubMed]
  • Turner, P. Dexfenfluramine. Its place in weight control. Drugs. 1990;39 Suppl 3:53–62. [PubMed]
  • Hunsinger, RN; Wright, D. A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat. Pharmacol Res. 1990 22(3):371–378.May–Jun; [PubMed]